logo-loader
viewIntrommune Therapeutics

Intrommune Therapeutics moving its peanut allergy treatment through the FDA approval process

Intrommune Therapeutics CEO Michael Nelson sat down with Proactive's Christine Corrado at the Biotech Showcase 2020 in San Francisco. The New York-based biotechnology company is developing is developing an oral mucosal immunotherapy treatment platform to treat food allergies including peanut allergies.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks slow down but show no signs of giving up last...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, eased 0.9% higher at 125.2 points. Elsewhere, the OTCQX Cannabis index fell 1% to 504.6 points. Buds today are TILT Holdings Inc (CSE:TILT) (OTCMKTS:TLLTF), Aphria Inc (TSE:APHA)...

14 hours, 54 minutes ago

2 min read